You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
|
|---|---|
| Published in |
Clinical Cancer Research, August 2012
|
| DOI | 10.1158/1078-0432.ccr-12-1221 |
| Pubmed ID | |
| Authors |
Luis J. Leandro-García, Susanna Leskelä, Carlos Jara, Henrik Gréen, Elisabeth Åvall-Lundqvist, Heather E. Wheeler, M. Eileen Dolan, Lucia Inglada-Perez, Agnieszka Maliszewska, Aguirre A. de Cubas, Iñaki Comino-Méndez, Veronika Mancikova, Alberto Cascón, Mercedes Robledo, Cristina Rodríguez-Antona |
| Abstract |
Peripheral neuropathy is the dose-limiting toxicity of paclitaxel, a chemotherapeutic drug widely used to treat several solid tumors such as breast, lung, and ovary. The cytotoxic effect of paclitaxel is mediated through β-tubulin binding in the cellular microtubules. In this study, we investigated the association between paclitaxel neurotoxicity risk and regulatory genetic variants in β-tubulin genes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Denmark | 1 | 2% |
| France | 1 | 2% |
| Unknown | 54 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 17% |
| Researcher | 7 | 12% |
| Student > Master | 6 | 10% |
| Professor | 5 | 9% |
| Student > Postgraduate | 5 | 9% |
| Other | 12 | 21% |
| Unknown | 13 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 31% |
| Agricultural and Biological Sciences | 8 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Neuroscience | 3 | 5% |
| Other | 4 | 7% |
| Unknown | 15 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2015.
All research outputs
#7,171,608
of 22,671,366 outputs
Outputs from Clinical Cancer Research
#6,492
of 12,566 outputs
Outputs of similar age
#53,201
of 167,800 outputs
Outputs of similar age from Clinical Cancer Research
#75
of 152 outputs
Altmetric has tracked 22,671,366 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 12,566 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 167,800 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 152 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.